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regulation, resulting in atypical hemolytic uremic
syndrome, predominantly in childhood. There are no trials
investigating treatment, and clinical practice is only
informed by retrospective cohort analysis. Here we
examined 175 children presenting with atypical hemolytic
uremic syndrome in the United Kingdom and Ireland for
factor H autoantibodies that included 17 children with
titers above the international standard. Of the 17, seven
had a concomitant rare genetic variant in a gene encoding
a complement pathway component or regulator. Two
children received supportive treatment; both developed
established renal failure. Plasma exchange was associated
with a poor rate of renal recovery in seven of 11 treated. Six
patients treated with eculizumab recovered renal function.
Contrary to global practice, immunosuppressive therapy to
prevent relapse in plasma exchange–treated patients was
not adopted due to concerns over treatment-associated
complications. Without immunosuppression, the relapse
rate was high (ﬁve of seven). However, reintroduction of
treatment resulted in recovery of renal function. All
patients treated with eculizumab achieved sustained
remission. Five patients received renal transplants without
speciﬁc factor H autoantibody–targeted treatment with
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eculizumab therapy for treatment of factor H
autoantibody–mediated atypical hemolytic uremic
syndrome rather than plasma exchange with or without
immunosuppression. Based on this retrospective analysis
we see no suggestion of inferior treatment, albeit the
strength of our conclusions is limited by the small sample
size.
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A typical hemolytic uremic syndrome (aHUS) iscommonly a consequence of complement dysregula-tion1 and is characterized by the triad of micro-
angiopathic hemolytic anemia, thrombocytopenia, and acute
kidney injury.1 It is rare, with an incidence of 0.42 per million
in the United Kingdom,2 but associated with signiﬁcant
morbidity and mortality.
aHUS is associated with mutations in genes encoding
complement regulatory proteins, complement factor H
(CFH), complement factor I (CFI), and membrane cofactor
protein (CD46)1 and in genes encoding the complement
components complement factor B (CFB) and C3 (C3).1 For
all of these complement mutations, penetrance is incomplete
and inﬂuenced by genetic modiﬁers in addition to environ-
mental triggering events.11261
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dysregulation, occurring consequent to the development of
autoantibodies directed against complement factor H
(FH)3 and factor I.4 Anti-FH–associated aHUS predomi-
nantly presents in childhood.3 The proportion of children
with aHUS who have anti-FH autoantibodies has been re-
ported as 5% to 25% in European cohorts5 and as high
as 56% in a large Indian cohort.6 Anti-FH autoantibodies
have been shown to be directed against different epitopes,
in some reports exclusively7,8 but in others predomi-
nantly9–11 located at the C-terminal of FH; a polyclonal
response to both N and C termini has also been re-
ported,10,12 and functional analyses have demonstrated
disruption of complement regulation by multiple
mechanisms.12
A strong association has been observed between anti-FH
autoantibodies and a homozygous deletion of CFHR1
and CFHR3, which encode complement FH–related
proteins 1 and 3. A deletion encompassing CFHR1 and
CFHR4 has also been reported in anti–FH- associated
aHUS, suggesting that it is the absence of FH-related
protein 1 that is most important in the development of
FH autoantibodies,1,9,12–19 and homozygous deletion of
CFHR1 has been identiﬁed in 79% to 89% of affected
individuals.5
Recent international consensus recommendations on the
management of aHUS highlight the uncertainty regarding
optimal management in patients with anti-FH autoanti-
bodies.20 In the United Kingdom and Ireland, our manage-
ment regimen, in contrast to practice in other countries, has
not incorporated immunosuppression. We report here our
experience of the management of pediatric FH autoantibody–
associated aHUS.
RESULTS
Patient details
A total of 175 children younger than 16 years of age from
the United Kingdom and Ireland who were referred to the
UK National aHUS center between 2000 and 2015 were
examined for FH autoantibodies. Twenty-two children
(13%) had positive FH autoantibody results; 17 of 22 chil-
dren (9.7% of the total cohort) had titers higher than the
international standard21 (100 relative units) on serum
samples obtained at the time of the initial presentation and
were included in this study (mean follow-up was 6 years, 5
months; range, 7 months to 13 years, 7 months). Five of 22
children did not meet the inclusion criteria (details in
Supplementary Methods). In all patients, a clinical diagnosis
of aHUS was made based on the presence of micro-
angiopathic hemolytic anemia, thrombocytopenia, and
acute kidney injury and the absence of Shiga toxin and
secondary causes.2 In 7 patients, a renal biopsy was per-
formed that demonstrated thrombotic microangiopathy.
The median age at presentation was 8 years (range, 1–15
years), and there was a male preponderance (male:female
ratio ¼ 11:6) (Figure 1).1262Clinical presentation
Clinical features at the time of presentation are shown in
Table 1. Prodromal gastrointestinal symptoms were
commonly observed, including abdominal pain (9/16 pa-
tients), vomiting (9/16 patients), and diarrhea (8/16 patients).
Infection was reported as a triggering event in 7 of 17 patients.
Extrarenal manifestations were reported in 8 of 16 patients
and included central nervous system involvement, hepatitis,
and pancreatitis. The serum creatinine and platelet values at
presentation are shown in Supplementary Figure S1.Complement analysis (N [ 17)
Initial complement levels are shown in Table 2 and
Supplementary Figure S2 (N ¼ 17). Thirteen patients had
normal C3 levels and 12 had normal C4 levels; 3 patients
(patients 2, 20, and 24) had both low C3 and low C4. Two
patients (patients 5 and 15) had low FH levels (Figure 2a),
and neither was found to have a rare genetic variant in CFH.
No patients had abnormal levels of CD46 or factor I.Anti-FH autoantibodies (N [ 17)
The anti-FH autoantibody titers at presentation are shown in
Figure 2b (range, 277–4000 relative units; median, 1594
relative units). In 9 of 17 patients, circulating FH/autoanti-
body immune complexes were detected, and these patients
had lower C4 levels (Supplementary Figure S3). In 10
patients, anti-FH autoantibody titer measurements at mul-
tiple time points up to 163 months after the ﬁrst presenta-
tion were available (Figure 3). In only 1 patient did the
FH autoantibody titer decrease to less than the international
standard. In 3 patients treated with eculizumab only, the titer
increased. In 5 patients who received immunosuppression in
association with current (n ¼ 4) or previous (n ¼ 1)
transplantation, 1 of whom was also treated with eculizumab,
the titers decreased, but 4 of 5 remained higher than the
international standard. In 2 patients (patients 2 and 17) who
did not receive eculizumab or immunosuppression and
recovered renal function and remain in remission, the titers
remain positive 12 (patient 2) and 9 (patient 17) years after
the ﬁrst presentation.
The binding epitopes of the anti-FH autoantibodies were
determined (Figure 4 and Supplementary Table S1). In 15 of
17 patients, the antibodies bound to the C-terminal; 14 of
these 15 patients had homozygous deletion of CFHR1,
whereas the 2 patients (patients 6 and 22) with antibodies that
did not bind to the C-terminal did not have a deletion of
CFHR1. In 12 of 15 patients with antibodies that bound to FH
short consensus repeats 19 and 20, there was also positive
binding to the C-terminal short consensus repeats 4 and 5 of
FH-related protein 1. In 2 patients, the autoantibodies
apparently cross-reacted with FH-related proteins 2 through 5
(Supplementary Table S2), but this was not conﬁrmed on
Western blotting (not shown), suggesting this interaction was
nonspeciﬁc or low-afﬁnity binding.Kidney International (2017) 92, 1261–1271
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Figure 1 | Age and sex at ﬁrst presentation of factor H autoantibody-associated atypical hemolytic uremic syndrome. The median age at
presentation was 8 years (range, 1–15 years). There was a male predominance: 65% male, 35% female.
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The results of the genetic analysis are shown in Table 3. In 7
of 17 patients, a coexisting rare genetic variant in a known
aHUS-associated gene was identiﬁed: CFI (n ¼ 4), CFH
(n ¼ 1), CD46 (n ¼ 1), and C3 (n ¼ 1); some have previously
been demonstrated to be functionally signiﬁcant.1 In 3 of
these 7 patients (patients 4, 5, and 12), established renal
failure (ERF) developed.
Fourteen of 17 patients had homozygous deletion of
CFHR1; in 11 patients, there was homozygous deletion ofTable 1 | Clinical features at presentation
Clinical feature Number of patients
Age, yr (N ¼ 17) Median: 8 yr; range: 1–15 yr
Sex (N ¼ 17) Male: n ¼ 11 Female: n ¼ 6
Prodrome
(N ¼ 16)
Abdominal pain n ¼ 9b
Vomiting n ¼ 9b
Diarrhea n ¼ 8b
Fever n ¼ 4
Other a
Clinical features
(N ¼ 16)
Hematuria n ¼ 12
Proteinuria n ¼ 13
Oligoanuria n ¼ 10
Hypertension n ¼ 9
Edema n ¼ 3
Triggering event
(N ¼ 17)
Infection n ¼ 7
None identiﬁed n ¼ 10
Extrarenal
manifestations
(N ¼ 16)
None n ¼ 8
Seizures n ¼ 3
Hepatitis n ¼ 2
Epistaxis n ¼ 2
Pancreatitis n ¼ 1
Altered consciousness n ¼ 1
Laboratory features at presentation Mean (range)
Hemoglobin, g/dl (N ¼ 17) 6.6 (4–9.1)
Platelet count, 109 (N ¼ 17) 52 (9–134)
Creatinine, mmol/l (N ¼ 17) 331 (61–1131)
Lactate dehydrogenase, U/L (N ¼ 16) 4460 (887–17,584)
Antinuclear antibodies (N ¼ 12) 1/12 positive 1:40
aOther prodromal symptoms reported in #2 patients: headache, malaise, cough,
visible hematuria, petechiae, and ﬂulike illness.
bTwelve patients had at least 1 gastrointestinal symptom (abdominal pain, vomiting,
diarrhea).
Kidney International (2017) 92, 1261–1271CFHR1/CFHR3, and in 3 patients, there was a combined
deletion of CFHR1/CFHR3 and CFHR1/CFHR4. In the total
cohort of children from the United Kingdom and Ireland who
were negative for anti-FH autoantibodies and underwent full
genetic analysis, homozygous deletion of CFHR1 was identi-
ﬁed in 11% (14/122); CFHR1 deletion was signiﬁcantly
associated with FH autoantibodies in aHUS (P < 0.01). Three
patients had 2 copies of CFHR1, CFHR3, and CFHR4 (pa-
tients 6, 19, and 22); ERF developed in all of them.
Treatment and evolution of the ﬁrst episode (N [ 17)
Eight of 17 patients required dialysis within the ﬁrst week of
presentation; ERF developed in 2 of 8 patients, but 5 of 8
patients were dialysis dependent for less than 1 week and fully
recovered renal function, and 1 of 8 patients (patient 24, treated
with eculizumab) was dialysis dependent for 5 weeks before
recovery of renal function (Supplementary Figure S4). Figure 5
summarizes the treatment and evolution of the ﬁrst episode.
Two of 17 patients were managed supportively, and ERF
developed in both. Eleven of 17 patients were treated with
plasma exchange (PEX), either alone (8 of 11 patients) or in
combination with i.v. IgG (2 of 11 patients) or corticosteroids
(1 of 11 patients). Of the patients treated with PEX (n ¼ 11),
ERF developed in 4; 7 recovered renal function, 5 of whom
subsequently experienced relapse. Four of 17 patients were
treated with eculizumab at the ﬁrst presentation and continue
on this therapy, and none have experienced any relapses. The
estimated glomerular ﬁltration rate (eGFR) at the most recent
follow-up for all patients is shown in Supplementary Table S3.
No patients were treated with immunosuppression at the ﬁrst
presentation. ERF developed in 6 of 17 patients and did so in all
following their initial presentation (Supplementary Figure S5).
No patients died.
Relapse (n [ 5)
Five of 17 patients experienced relapse (Table 4). All had been
treated with PEX at the ﬁrst presentation. Four of 5 patients
experienced a single relapse 43 to 1254 days after the initial
presentation; 2 were treated with PEX alone, 1 with PEX plus1263
Table 2 | Initial complement antigenic levels: C3, C4, CD46, and factor H (FH), factor I (CFI)
Patienta C3(0.68–1.38 g/l) C4 (0.18–0.6 g/l) CD46 FH (0.35–0.59 g/l) FI (38–58 mg/l)
2 0.57 0.15 Not tested 0.44 70
4b 0.89 0.3 Normal 0.52 41
5b 0.92 0.2 Not tested 0.29 Not tested
6b 1.08 0.36 Not tested 0.5 74
10 1.06 0.13 Not tested 0.45 68
12b 1.02 0.19 Normal 0.57 62
14 0.65 0.31 Normal 0.43 41
15 0.77 0.29 Normal 0.23 84
16 0.95 0.51 Normal 0.53 42
17 1.06 0.24 Normal 0.53 44
18 1.1 0.18 Normal 0.48 52
19b 1.23 0.52 Normal 0.48 70
20 0.51 0.16 Not tested 0.48 59
21 1.61 0.29 Normal 0.77 73
22b 1.22 0.2 Normal 0.73 78
23 0.91 0.16 Not tested 0.39 65
24 0.61 0.14 Normal 0.51 62
FH, factor H; FI, factor I.
aIdentiﬁcation numbers for patients 2, 4, 5, 6, 10, and 12 correspond to those in a previous publication.9
bIndicates patients in whom established renal failure developed.
c l i n i ca l i nves t iga t i on V Brocklebank et al.: Factor H autoantibody aHUSrituximab (patient 21, 16 years 6 months of age at the time of
relapse and was managed by the adult nephrology service),
and 1 was treated with eculizumab. Three patients have an
eGFR of >60 ml/min per 1.73 m2, and 1 patient has an eGFR
of 53 ml/min per 1.73 m2, and none has experienced further
relapse. One of 5 patients experienced multiple relapses
and was treated with regular PEX for 7 years. PEX was
withdrawn in 2012 with no further relapses; 1 year after PEX
withdrawal (at last follow-up under pediatric care), the eGFR
was >60 ml/min per 1.73 m2.Figure 2 | (a) Initial titers of factor H autoantibody and circulating im
FH autoantibody titer was above the international consensus positive th
patients, circulating immune complexes were detected. (b) Initial factor
range. Fifteen patients (88%) had a normal FH level. Two patients (12%
patient with a rare genetic variant in CFH had a normal FH level. aFH, F
relative units.
1264Outcome of renal transplantation (n [ 6)
Five of the 6 patients in whom ERF developed received renal
transplants (1 patient received 2 transplants) (Table 5). One
patient has been ineligible for transplantation due to medical
problems. In 1 patient (patient 4), who has a functionally
signiﬁcant CFI mutation in addition to FH autoantibodies, a
donor after cardiac death transplant resulted in primary
nonfunction. Six months later, a living related ABO-
incompatible transplantation was performed. Because of the
ABO incompatibility, the recipient received rituximabmune complexes of factor H/autoantibody. In all patients the initial
reshold of 100 relative units (dashed line). In some, but not all
H level. The dashed line represents the lower limit of the normal
) had a low FH level, and neither had a CFH rare genetic variant. The
H autoantibody; CiC, circulating immune complexes; FH, factor H; RU,
Kidney International (2017) 92, 1261–1271
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Figure 3 | Changes in factor H autoantibody titers over time for 10 patients. In 10 patients, anti–FH autoantibody titer measurements
at multiple time points up to 163 months after the ﬁrst presentation were available. In 1 patient, the titer fell below the international
standard. The maintenance treatment received by each patient is shown. E, on eculizumab; FH, factor H; HD, hemodialysis; N, no
speciﬁc maintenance treatment; T, transplanted (immunosuppressed).
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titers to an acceptable level. Nine hours after transplantation,
recurrent aHUS was evident. This was successfully treated
with eculizumab, which has been continued, and graft
function remains good (eGFR: 47.6 ml/min per 1.73 m2).NC
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Figure 4 | Autoantibody reactivity with short factor H fragments. Aut
16–18, and 19–20) and a FH–related protein 1 fragment (SCR 4–5). In 31
the antibodies were monoclonal, and in 91% of these the binding was
antibodies that bound predominantly to SCRs 1–7. FHR1, factor H–relate
short consensus repeat.
Kidney International (2017) 92, 1261–1271The other 4 patients received deceased donor kidneys and
standard immunosuppression according to the local trans-
plant unit protocol (Table 5) with no speciﬁc autoantibody-
targeting treatment, and none experienced aHUS recur-
rence; 3 of 4 patients continue to have good graft function7
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Figure 5 | Evolution of ﬁrst episode according to treatment. In
children managed supportively, ERF did not develop; treatment with
PEX was associated with a high rate of relapse if ERF did not occur,
and ERF did not develop in any patient treated with eculizumab or no
patient experienced relapse. No patient was treated with
immunosuppression at the initial presentation. *Includes PEX alone
(n ¼ 8), PEX plus i.v. IgG (n ¼ 2), PEX plus corticosteroids (n ¼ 1).
**Deﬁned as recurrence >1 month after presentation and >15 days
after disease remission. †One patient (patient 10) experienced
multiple relapses and was maintained on regular PEX. ERF,
established renal failure; PEX, plasma exchange.
Table 3 | Genetic analysis
Patienta Rare genetic variant
Copies
of CFHR1
Copies
of CFHR3
Copies
of CFHR4
2 NMD 0 0 2
4b CFI c.1216C>T p.(Arg406Cys) 0 1 1
5b C3 c.1898A>G p.(Lys633Arg) 0 0 2
6b NMD 2 2 2
10 CFI c.1534þ5G>T 0 1 1
12b CFH c.2850G>T p.(Gln950His) 0 0 2
14 CFI c.1456T>C p.(Trp486Arg)c 0 0 2
15 NMD 0 0 2
16 CFI c.859G>A p.(Gly287Arg) 0 0 2
17 CD46 c.919A>C p.(Thr307Pro) 0 0 2
18 NMD 0 0 2
19c NMD 2 2 2
20 NMD 0 1 1
21 NMD 0 0 2
22c NMD 2 2 2
23 NMD 0 0 2
24 NMD 0 0 2
NMD, no mutation detected.
Rare genetic variants (deﬁned as observed frequency of <1%, and resulting in a
nonsynonymous amino acid substitution or potentially affecting a splice site)
identiﬁed following mutation screening of the CFH, CD46, CFI, CFB, C3 and DGKE
genes, and number of copies of CFHR1, CFHR3 and CFHR4 as determined by MPLA
analysis.
aIdentiﬁcation numbers for patients 2, 4, 5, 6, 10, and 12 correspond to those in a
previous publication.9
bHomozygous variant (all other variants are heterozygous).
cIndicates patients in whom established renal failure developed.
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1266(eGFR: 48.4 ml/min per 1.73 m2 in 1 patient and >60 ml/
min per 1.73 m2 in 2 patients), and 1 of 4 transplants failed
after 7.5 years due to severe antibody mediated rejection.
DISCUSSION
In this report, we describe the phenotypic, immunologic, and
genetic characteristics of children younger than 16 years of
age presenting in the United Kingdom and Ireland since 2000
with FH autoantibody–associated aHUS and evaluate treat-
ment and outcomes.
The median age at presentation was 8 years, and there was
a male predominance, which concurs with other studies.6,15,22
Similar to other European cohorts (Supplementary
Table S4),15,22,23 we found that gastrointestinal prodromal
symptoms were commonly reported, which may lead to dif-
ﬁculty differentiating from Shiga toxin–associated HUS with a
consequent delay in appropriate treatment.
The clinical presentation of the patients in an Indian
cohort reported by Sinha et al.6 is different, with diarrhea
reported in only 9%; the other striking difference in this
cohort is the higher incidence of anti-FH autoantibodies
(56% compared with 13% in this study, 5%–25% in Euro-
pean cohorts and 29.4% in a Korean cohort)5,6,24
(Supplementary Table S4). It may be that environmental
factors, for example, endemic infectious disease, or as yet
unidentiﬁed genetic factors are having a signiﬁcant inﬂuence
on disease manifestation.
In our study, 4 of 17 patients had a low C3 level, which is
a lower proportion than in other cohorts (Supplementary
Table S4),6,15,19,22,24,25 and we did not ﬁnd that C3 level
correlated with prognosis, in contrast to Dragon-Durey
et al.22 and Sinha et al.6 Five of 17 patients had a low C4
level despite FH being a complement alternative pathway
regulator; other groups have also reported low C4 levels in a
small proportion of patients.9,15,19,25 It is interesting that all
patients with low C4 also had circulating FH/autoantibody
immune complexes and that there was a correlation be-
tween the immune complexes titer and C4 level
(Supplementary Figure S3). This could suggest that the
complexes themselves are activating the classic pathway of
complement.
In 10 patients, anti-FH autoantibody titer measurements
at multiple time points were available (Figure 3). In 5 pa-
tients who had transplants and therefore receive long-term
immunosuppression, the titers have decreased. It is inter-
esting that in 3 patients who have been treated with eculi-
zumab for several years and remain well, the autoantibody
titers have increased compared with the titers at presenta-
tion. It is also interesting that 2 patients still have positive
autoantibody titers 9 and 12 years after presentation, yet
only 1 experienced a relapse (single relapse at 88 days), and
both remain well despite not receiving any speciﬁc long-
term treatment.
Low FH levels were reported previously in 22% to 29%22,25
(1 study included 2 patients with a CFH rare genetic
variant).25 In our study, 2 of 17 patients had a low FH levelKidney International (2017) 92, 1261–1271
Table 4 | Incidence and treatment of relapse (N [ 5)
Patient Duration of PEX at ﬁrst presentation Time to relapsea after ﬁrst presentation Treatment of relapse Outcome
2 PEX  32 exchanges 88 days PEX Creatinine 100 mmol/l
eGFR >60 ml/min per 1.73 m2
No further relapse
10 PEX  30 exchanges Multiple relapses PEXb Creatinine 83 mmol/l
eGFR >60 ml/min per 1.73 m2
Relapse-free since 2012
16 PEX  8 mo 1254 days Eculizumab Creatinine 86 mmol/l
eGFR 53 ml/min per 1.73 m2
No further relapse
18 PEX  5 exchanges 43 days PEX Creatinine 89 mmol/l
eGFR >60 l/min per 1.73 m2
No further relapse
21 PEX  15 exchanges 266 days PEX þ rituximab Creatinine 87 mmol/l
eGFR >60 ml/min per 1.73 m2
No further relapse
eGFR, estimated glomerular ﬁltration rate; PEX, plasma exchange.
The 2 patients treated with PEX at ﬁrst presentation who recovered renal function and did not experience relapse were patient 17 (PEX twice weekly for 2 months) and patient
23 (PEX  6 exchanges); both patients have an eGFR of >60 ml/min per 1.73 m2.
eGFR by Schwartz formula for patients younger than 18 years of age at last follow-up (patients 10, 16, and 18) and by an abbreviated Modiﬁcation of Diet in Renal Disease
equation for patients older than 18 years of age at the last follow up (patients 2 and 21).
aRelapse deﬁned as recurrence >1 month after presentation and >15 days after disease remission.
bPatient 10 experienced multiple relapses and was PEX dependent between 2004 and 2011 (PEX every 4 weeks), but has not experienced further relapse since PEX was
withdrawn in 2012.
V Brocklebank et al.: Factor H autoantibody aHUS c l i n i ca l i nves t iga t iondespite having no rare genetic variants in CFH; both patients
had circulating immune complexes, and we assume the low
FH level is secondary to this complexing.
We identiﬁed rare genetic variants in genes encoding
complement components or complement regulators in 7 of
17 patients, and at least some are functionally signiﬁcant. In
comparison, Dragon-Durey et al.22 did not identify any rare
genetic variants in 26 patients, but other studies have iden-
tiﬁed rare genetic variants in 4% to 33% of patients with FH
autoantibodies15,23,25,26 (Supplementary Table S4); genetic
analysis data have not been reported for the Indian cohort.6
This has crucial implications for management: if treatment
is focused exclusively on antibody removal and reduction
without considering that a concomitant functionally signiﬁ-
cant rare genetic variant may also be contributing to the
disease, then it may be ineffective. We therefore recommend
genetic analysis of all patients with FH autoantibodies.
In agreement with other studies,6,12,14,15,17,19,22–25 we
found that the majority of patients with anti-FH autoantibody
aHUS have a homozygous deletion of CFHR1; Nozal et al.10
previously demonstrated that the presence of deﬁciency of
FH-related protein 1 is associated with differences in antibody
binding, and this was also the case in our study. Whereas
most patients with a homozygous deletion of CFHR1 had
antibodies that predominantly bound to the C-terminal of
FH, in 2 of the 3 patients with 2 copies of CFHR1, the an-
tibodies bound predominantly to the N-terminal of FH.
Historically, anti-FH autoantibody–associated aHUS was
associated with a high rate of ERF (27%–63%).6,19,22,25
Consistent with this, in our cohort, ERF developed in 6 of
17 patients, although this may reﬂect late presentation rather
than unsuccessful treatment. Lee et al.24 reported the only
study in which ERF did not develop in any patients in a
Korean cohort of 15 patients. In our study, 8 of 17 patientsKidney International (2017) 92, 1261–1271required dialysis within 1 week of presentation, but 6 of 8 of
these fully recovered renal function, so dialysis requirement at
presentation did not predict poor renal outcome.
There are no clinical trials investigating treatment of anti-
FH autoantibody aHUS, and evidence comes only from
retrospective cohorts. In the 2 patients in our cohort who
received supportive treatment only, ERF developed in both,
and in a French cohort, only 1 of 6 patients managed sup-
portively had no renal sequelae.22 In the United Kingdom and
Ireland, of the 11 patients treated with PEX at initial
presentation, ERF developed in 4, a rate in keeping with other
reports.22
High rates of late relapse have been observed in those
patients successfully treated with PEX22 following cessation,
and many centers have recommended additional immuno-
suppression. It has been demonstrated that this results in
signiﬁcant reductions in autoantibody titer.6,27,28 The United
Kingdom and Ireland are unusual in not adopting immu-
nosuppressive regimens after PEX due to concerns about the
high incidence of concomitant rare genetic variants in com-
plement genes and the potential side effects of cytotoxic
therapy in a pediatric population, which include infectious
complications, gonadal toxicity, and long-term risk of ma-
lignancy.29 Five of the 7 children who recovered renal func-
tion after PEX subsequently experienced relapse, but careful
monitoring with reintroduction of treatment resulted in re-
covery of renal function in all cases.
Dragon-Durey et al.22 reported sustained remission and
normal renal function in 3 patients treated with PEX plus
cyclophosphamide or mycophenolate mofetil, and Sana
et al.28 also reported good outcomes in 4 patients treated with
PEX plus corticosteroids plus pulsed cyclophosphamide; in
this latter study, no treatment-related adverse events were
observed. Guan et al.30 reported the successful treatment of 41267
Table 5 | Outcome of transplantation (N [ 6)
Patient Transplant
Age at
transplantation
Time after ﬁrst
presentation of aHUS HLA mismatch
Treatment
before transplantation
Induction
immunosuppression
Maintenance
immunosuppression Outcome
4a DCD (en bloc) 8 yr, 9 mo 5 yr Unknown None Unknown Unknown Primary nonfunction
4a LRTb
ABOi
9 yr, 3 mo 5 yr, 6 mo 1:1:1 Rituximab and
immunoadsorptionc
Basiliximab Tacrolimus, MMF,
prednisolone
Immediate recurrence,d
eculizumab, creatinine: 72 mmol/l,
eGFR: 47.6 ml/min
per 1.73 m2
(follow-up 9 mo)
5 DBD 12 yr, 6 mo 1 yr, 10 mo 1:1:0 None Basiliximab Tacrolimus, azathioprine,
prednisolone
Transplant failed after
7 yr 6 mo (severe
AMR postpartum)
12 DBD 10 yr 1 yr, 5 mo Unknown None Basiliximab MMF, prednisolone Creatinine: 80 mmol/l,
eGFR: >60 ml/min per 1.73 m2
(follow-up 6 yr 9 mo)
19 DBD 11 yr, 5 mo 1 yr, 5 mo 1:1:0 None Unknown Tacrolimus, azathioprine,
prednisolone
Creatinine: 109 mmol/l,
eGFR: 48.4 ml/min per 1.73 m2
(follow-up: 3 yr 11 mo)
22 DCD 9 yr, 9 mo 2 yr Unknown None Basiliximab Tacrolimus (purine antagonist
stopped)
Creatinine: 83 mmol/l,
eGFR: >60 ml/min per 1.73 m2
(follow-up: 2 yr 5 mo)
ABOi, ABO incompatible; aHUS, atypical hemolytic uremic syndrome; AMR, antibody-mediated rejection; DBD, donor after brain death; DCD, donor after cardiac death; eGFR, estimated glomerular ﬁltration rate; LRT, living related
transplant; MMF, mycophenolate mofetil.
eGFR by Schwartz formula (all patients were younger than 18 years of age at last follow-up).
aConcomitant functionally signiﬁcant CFI mutation.
bLRT: living donor underwent genetic screening; no rare genetic variant, 0 copies CFHR1, 1 copy CFHR3.
cTreatment given because of ABO incompatibility: rituximab 1 month before transplant, and immunoadsorption 4 (anti–A titers reduced from 1:128 to 1:8).
dRecurrence 9 hours after transplantation. Successfully treated with eculizumab.
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mofetil. Sinha et al.6 reported the outcome of PEX plus
immunosuppression in an Indian cohort of 138 children who
received induction therapy with cyclophosphamide (n ¼ 49)
or rituximab (n ¼ 18) and maintenance therapy comprising
corticosteroid with or without mycophenolate mofetil or
azathioprine (n ¼ 47). ERF developed in 32.8%, the relapse
rate was low (11.5%), and the mortality rate was 16.4%, with
the deaths attributed to complications of renal failure or
sepsis.6 It is noteworthy that in this cohort, 4 patients expe-
rienced relapse despite maintenance immunosuppression.6
In a recent review, Dragon-Durey et al.5 summarized
outcomes according to treatment strategy for 243 patients in
published studies; for patients treated with PEX and immu-
nosuppression compared with those treated with PEX alone,
the relapse rate was 10.7% compared with 28.7%, and the
development of chronic kidney disease stage 4/5 or death was
14.3% compared with 35.6%.
Successful use of the terminal complement inhibitor
eculizumab in anti-FH autoantibody–associated aHUS has
been reported in a small number of patients in trials31,32 and
case reports.33–37 In our study, 6 patients were treated with
and continue on eculizumab: 4 of 6 were started on eculi-
zumab at the ﬁrst presentation, 1 of 6 at relapse, and 1 of 6
following early recurrence after transplantation, with sus-
tained remission observed in all; 3 patients have stable
chronic kidney disease stage 3A, and 3 patients have an
eGFR >60 ml/min per 1.73 m2. There have been no deaths
in our cohort, and no adverse events associated with eculi-
zumab. All patients started on eculizumab remain on
continuous treatment regardless of autoantibody titer; this is
consistent with our current practice in the United Kingdom
for all patients with aHUS. Systematic assessment of eculi-
zumab withdrawal in the context of a clinical trial is
required, and a prospective trial is due to start recruiting in
the United Kingdom.
There is currently insufﬁcient evidence for consensus
guidelines on the management of renal transplantation spe-
ciﬁcally in individuals with anti-FH autoantibody–associated
aHUS,20 and practice is guided by retrospective analysis of
outcomes in published cases, of which there are only 27
transplants in 21 patients,5 including 3 living related trans-
plants.38,39 There has been considerable variation in peri-
transplant management strategy, including PEX, rituximab,
i.v. IgG, and eculizumab, as well as no speciﬁc autoantibody-
targeting therapy.5,40,41 In their review, Dragon-Durey et al.5
report that for 9 grafts with no speciﬁc management, 5
were lost because of disease recurrence, and for 12 grafts with
speciﬁc management (including PEX, rituximab, i.v. IgG, and
eculizumab), recurrence was seen in 1 (and treated success-
fully with PEX and eculizumab42), and no grafts were lost.
We report the outcomes of renal transplantation in 5 pa-
tients with anti-FH autoantibody–associated aHUS (Table 5).
None of the patients received speciﬁc FH autoantibody–
targeting treatment before transplantation, although 1 patient
received rituximab and immunoadsorption because of ABOKidney International (2017) 92, 1261–1271incompatibility, and that patient was the only one in whom
aHUS recurrence occurred, although this may have been a
consequence of the functionally signiﬁcant CFI mutation
rather than the FH autoantibodies.
There is no clearly effective strategy to accurately predict
the risk of recurrence following transplantation, and our
current practice takes a pragmatic approach: if the anti-FH
autoantibody titer is above the positive threshold or if a
concomitant functionally signiﬁcant rare genetic variant is
identiﬁed, then we recommend prophylactic eculizumab.
The limitations of this study relate to the retrospective and
observational methodology, and the signiﬁcant technological
advancement (mainly, the availability of eculizumab) that
occurred over the study period. The small sample size is the
major factor that limits the strength of the conclusions that
can be drawn.
In summary, we report that all patients treated with
eculizumab at initial presentation recovered renal function,
whereas PEX resulted in only a 64% recovery rate, with
supportive treatment universally ineffective. In much of
Europe and India, immunosuppression has been added with
the aim of preventing disease relapse. This practice was
not adopted in the United Kingdom due to concerns over
infectious complications and the high incidence of
concomitant rare genetic variants. In the absence of
immunosuppressive therapy, in those who responded to
PEX, the relapse rate was high (71%); however, close
monitoring and reintroduction of treatment resulted in re-
covery of renal function in all cases. In comparison, no
patient who continued on eculizumab had recurrent disease.
Our current practice is to initiate eculizumab therapy rather
than plasma exchange with or without supplemental
immunosuppression for FH autoantibody–mediated aHUS,
and based on this retrospective analysis, we see no suggestion
that this is inferior, albeit the strength of our conclusions is
limited by the small sample size.METHODS
Patients
All children younger than 16 years of age from the United Kingdom
and Ireland presenting since 2000 with aHUS and anti-FH autoan-
tibodies at a titer above the international consensus positive
threshold of 100 relative units21 were identiﬁed from the UK Na-
tional Renal Complement Therapeutic Centre. A total of 175 chil-
dren younger than 16 years of age from the United Kingdom and
Ireland were tested for anti-FH autoantibodies. Twenty-two children
(13%) were positive. Of these, 17 were included in this study, and 5
were excluded (details in Supplementary Methods). Serum samples
taken at the time of presentation were available for all included
patients. Immunologic and genetic data from 6 of these patients were
reported previously by our group9; the patient identiﬁcation
numbers used here for these patients (patients 2, 4, 5, 6, 10, and 12)
are consistent with those used in the previous publication to allow
for direct comparison. Seven patients included previously were
excluded from this study because they were not from the United
Kingdom and Ireland (patients 1, 7, 8, 9, 11, and 13) or the anti-FH
autoantibody titer was found to be below the international consensus1269
c l i n i ca l i nves t iga t i on V Brocklebank et al.: Factor H autoantibody aHUSpositive threshold (patient 3). Data for patients 1243 and 16 and 2144
were published previously. The details of the eGFR calculations are
included in Supplementary Methods. Relapse was deﬁned as disease
recurrence >1 month after initial presentation and >15 days after
disease remission.
The study was approved by the Northern and Yorkshire Multi-
Centre Research Ethics Committee, and informed consent ob-
tained in accordance with the Declaration of Helsinki.
FH autoantibody assay
The consensus assay was performed as previously described,21 and
the FH autoantibody was conﬁrmed by Western blotting (details
provided in Supplementary Methods).
Complement assays
C3 and C4 levels were measured by rate nephelometry (Beckman
Coulter Array 360, Beckman Coulter; High Wycombe, United
Kingdom). FH and factor I levels were measured by radio-
immunodiffusion (Binding Site, Birmingham, UK). The normal
ranges were C3 (0.68–1.38 g/l), C4 (0.18–0.60 g/l), FH (0.35–0.59 g/
l), and factor I (38–58 mg/l). CD46 was measured as previously
described.45
Genetic analysis
Mutation screening of CFH,46 CFI,47 CFB,48 CD46,49 C3,50 and
DGKE51 was undertaken using Sanger sequencing, as previously
described. Screening for chromosomal rearrangements affecting
CFH, CFHR1, CFHR2, CFHR3, CFHR4, CFHR5, CFI, and CD46 was
undertaken using multiplex ligation-dependent probe ampliﬁcation,
as previously described.52,53
Statistical analyses
Patient characteristics were examined using descriptive statistics for
continuous variables (mean, median) and categorical variables
(number, %). Laboratory data are presented as mean (range). Data
were analyzed by a 2-tailed Student t test. A P value <0.05 was
considered to be statistically signiﬁcant. Renal survival was examined
using Kaplan-Meier analysis.
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Figure S1. Serum creatinine and platelet values at presentation.
Figure 2. Initial complement antigenic levels. (A) C3. Normal in 76%
of patients. (B) C4. Normal in 71% of patients. (C) Factor I. Normal in1270all patients. The dashed lines represent the lower limit of the normal
ranges.
Figure S3. C4 level and factor H (FH) autoantibody circulating
immune complexes. RU, relative units.
Figure S4. Outcome according to dialysis requirement at
presentation; 75% of patients who required dialysis within 1 week of
presentation fully recovered renal function. *Deﬁned as dialysis
within the ﬁrst week of presentation. **Deﬁned as recurrence >1
month after presentation and >15 days after disease remission.
yManagement: supportive: 1, PEX: 1. zManagement: PEX: 4,
eculizumab: 2. ERF, established renal failure; PEX, plasma exchange.
Figure S5. Kaplan-Meier survival curve showing probability of renal
survival. Established renal failure developed in 35% of patients, and in
all cases, this occurred at the ﬁrst presentation of atypical hemolytic
uremic syndrome. There were no deaths.
Table S1. Autoantibody reactivity with short factor H fragments.
Table S2. Initial titers of factor H autoantibody (aFH), circulating
immune complexes (CiC), and autoantibody reactivity with factor
H–related proteins 1 to 5 (positive threshold >100 relative units).
Table S3. Treatment modality and resultant renal function.
Table S4. Comparison with other cohorts.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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